Compare IDEXX Laboratories, Inc. (IDXX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Prologis Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Prologis Inc trades at $140.73 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 2.9× IDEXX Laboratories, Inc.'s market cap, and Prologis Inc pays a 3.07% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PLD | |
|---|---|---|
Market Cap | $46.22B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $149.96 |
52-Week Low | $526.44 | $105.44 |
Enterprise Value | $47.12B | $167.31B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Prologis (PLD) trades at $140.46, up 1.25% on the day, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, and the company announced a major $18.8 billion acquisition of Segro (WSJ, 2026-08-04). Valuation ratios are elevated, with a P/E of 31.07 and P/S of 14.54, while profitability remains robust with a net income margin of 45.79%.
The outlook is mixed: analyst consensus is bullish with a $159.22 price target, but the Segro acquisition introduces integration risks and leverage concerns. Upside hinges on successful merger execution and sustained industrial real estate demand, while downside risks include debt load and economic slowdowns impacting logistics property valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
